New Delhi: Drug firm Lupin on Wednesday said it has received approval from the US health regulator to market a generic medication to treat seizures.

The Mumbai-based firm has received a nod from the USFDA for its abbreviated new drug application (ANDA) for Brivaracetam Oral Solution (10 mg/mL), it said in a statement.

Brivaracetam is the bioequivalent to UCB, Inc's Briviact Oral Solution (10 mg/mL) and is indicated for the treatment of partial-onset seizures in patients.

Following the approval, the company initiated the launch of Brivaracetam Oral Solution in the US, it stated.

As per industry estimates, Brivaracetam Oral Solution had an estimated annual sale of USD 135 million in the US.

Lupin shares were trading 0.98 per cent up at Rs 2,273.10 apiece on the BSE. (PTI)